LT
ABBV icon

Legacy Trust’s AbbVie ABBV Stock Holding History

Legacy Trust’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Sell
7,861
-316
-4% -$68K 0.35% 62
2026
Q1 		$1.78M Buy
8,177
+814
+11% +$181K 0.34% 60
2025
Q4 		$1.68M Buy
7,363
+321
+5% +$73.1K 0.31% 62
2025
Q3 		$1.63M Buy
7,042
+4,583
+186% +$933K 0.32% 63
2025
Q2 		$456K Sell
2,459
-52
-2% -$9.66K 0.11% 107
2025
Q1 		$526K Sell
2,511
-360
-13% -$70K 0.13% 103
2024
Q4 		$510K Sell
2,871
-51
-2% -$9.38K 0.12% 103
2024
Q3 		$577K Buy
2,922
+370
+14% +$69.1K 0.13% 103
2024
Q2 		$438K Sell
2,552
-101
-4% -$16.7K 0.11% 107
2024
Q1 		$483K Sell
2,653
-668
-20% -$115K 0.12% 107
2023
Q4 		$515K Sell
3,321
-119
-3% -$17.3K 0.13% 103
2023
Q3 		$513K Buy
3,440
+16
+0.5% +$2.35K 0.15% 97
2023
Q2 		$461K Sell
3,424
-150
-4% -$22K 0.13% 109
2023
Q1 		$570K Buy
3,574
+210
+6% +$32.1K 0.17% 93
2022
Q4 		$544K Buy
+3,364
New +$516K 0.17% 92

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Legacy Trust's ABBV Position: Q2 2026 in Review

Legacy Trust reduced its AbbVie (ABBV) stake by 3.9% in Q2 2026, selling an estimated $68K and leaving 7,861 shares worth $1.98M. The position accounts for 0.35% of the portfolio, ranked #62.

Legacy Trust first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Legacy Trust held 7,861 shares of AbbVie worth $1.98M as of Q2 2026.
  • Legacy Trust sold 316 AbbVie shares in Q2 2026, an estimated $68K.
  • AbbVie made up 0.35% of Legacy Trust's portfolio in Q2 2026, its #62 holding.
  • Legacy Trust first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Legacy Trust's 13F filing for Q2 2026, filed 31 Jul 2026.